Engrail Therapeutics has completed a series A round led by Nan Fung Life Sciences as it targets a validated mechanism-based approach to nervous system treatments.

Nan Fung Life Sciences, the healthcare investment arm of property development conglomerate Nan Fung, led a $32m series A round for Engrail Therapeutics, a US-based developer of treatments for nervous system disorders. Founded in 2019, Engrail is working on medicines that are focusing on the nervous system, using a biological understanding of disease to create…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.